drugset / Trial / NCT02452996
Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers
RandomizedQuadruple-blindTreatment
Summary
In this clinical study, the safety and tolerability of GNbAC1 as a treatment for MS patients will be evaluated in healthy male volunteers.
Timeline
- Start
- 2015-04
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Temelimab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Comparator | Temelimab | Monoclonal antibody | 18 mg/kg | Intravenous |
| Comparator | Temelimab | Monoclonal antibody | 36 mg/kg | Intravenous |
Indications
No indication recorded.